Psychosis is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Psychosis have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Psychosis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psychosis overview
Psychosis is a condition that affects the mind and causes a loss of contact with reality. People with psychosis may experience hallucinations (seeing or hearing things that are not there) and delusions (believing things that are not true). Psychosis can be a symptom of various mental disorders, such as schizophrenia, bipolar disorder, or severe depression. It can also be triggered by stress, trauma, or substance use. Psychosis can affect a person’s thoughts, feelings, and behavior, and interfere with their daily functioning. Treatment for psychosis usually involves antipsychotic medication and psychotherapy. Early intervention can improve the outcome and recovery of people with psychosis.
For a complete picture of PTSR and LoA scores for drugs in Psychosis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
